Gelonghui November 29丨Pilot Pharmaceutical Biotechnology (00399.HK) announced that for the six months ended September 30, 2023, the company's revenue was approximately HK$3,700,000, a decrease of about 9.7% over the previous year. The decrease was mainly due to a decrease in the operations of the Beauty Equipment and Products Trading Division during the current financial period.
The Group recorded a profit of approximately HK$193,700,000 attributable to company owners during the period, while a loss of HK$115,700,000 was recorded in the previous financial period. The conversion of losses to profits was mainly due to non-cash items arising from the completion of the third revision of Convertible Bonds III during the current financial period.